In NSCLC, ALK rearrangement is the most common type, accounting for 5–6% of patients, this mutation induces an oncogenic ALK tyrosine kinase that activates many downstream signaling pathways, thus leading to elevated cell proliferation and survival32. Here, ALK is linked to non-small cell lung carcinoma.